JP2015110560A - Novel imidazole compound - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel imidazole compound having excellent storage stability and fine curability as a one-pack type curing agent for curing an epoxy resin, an episulfide compound or the like, and useful as an easily-handleable curing agent.SOLUTION: There is provided an imidazole compound shown by formula (I) (R1 and R2 are each independently a C4-20 alkyl group; R3-R5 are each independently H, a C1-17 alkyl group, a C6-17 aryl group or a C3-15 heteroaryl group containing at least one hetero atom).

Description

  The present invention relates to a novel imidazole compound useful as a curing agent for an anion curable compound, for example.

  As a curing agent for curing an anion curable compound such as an epoxy compound or an episulfide compound, a curing agent for an anion curable compound (hereinafter also referred to as an imidazole curing agent) made of an imidazole compound is used. However, the liquid imidazole curing agent has a problem that the storage stability is remarkably low when used as a one-component curing agent.

  It is known to use an epoxy-imidazole adduct type curing agent as a measure for improving the storage stability of an imidazole curing agent (see, for example, Patent Document 1). However, since this curing agent is in a powder form at room temperature, it requires "a complicated mixing operation", "has a problem with dispersion stability", "the curing agent does not reach the details of the base material, and curing failure occurs. There was a problem such as “wake up”.

On the other hand, a ketimine type latent curing agent in which a primary amine is generated as a curing active species by moisture is known as an anion-generating curing agent that achieves both curability and storage stability (see, for example, Patent Document 2). ). However, only a primary amine can be generated by the mechanism for making the curing agent have a potential, and this mechanism cannot be applied to an imidazole-based curing agent having no primary amine. This curing agent also has a problem that outgassing occurs during curing.
Therefore, development of a novel imidazole compound useful as a curing agent having excellent storage stability and good curability even when used as a one-component curing agent has been desired.

JP 2000-1526 A JP 2002-249544 A

  The object of the present invention is to provide a novel imidazole compound useful as a curing agent that has excellent storage stability and good curability even when used as a one-part curing agent, and is easy to handle. It is to provide.

As a result of diligent efforts, the present inventors have found that a novel imidazole compound in which the 1-position of the imidazole skeleton is protected with a predetermined protecting group solves the above problem.
Since the imidazole compound of the present invention has a structure in which the bond at the 1-position of the imidazole skeleton is easily cleaved by heat, the nitrogen atom at the 1-position of the imidazole skeleton is protected by a group that easily forms a double bond by heat. It is designed on the basis of the technical idea that it is combined.
Specifically, the protecting group of the imidazole compound of the present invention has a structure having two electron-attracting groups in the ethyl group extending from the 1-position of the imidazole skeleton, and is eliminated at less than 50 ° C. under normal pressure conditions. Difficult, has a function of desorption at 50 ° C.

〔式中、Ｒ１及びＲ２はそれぞれ独立して炭素数４〜２０のアルキル基であり、
Ｒ３〜Ｒ５はそれぞれ独立して水素原子、炭素数１〜１７のアルキル基、炭素数６〜１７のアリール基、及びヘテロ原子を少なくとも１つ含む炭素数３〜１５のヘテロアリール基からなる群から選択されるいずれか１つの原子又は基である。
ただし、Ｒ１及びＲ２がいずれもブチル基であり、Ｒ３〜Ｒ５がいずれも水素原子である化合物を除く。〕 That is, the present invention provides an imidazole compound represented by the following general formula (I).

[Wherein, R 1 and R 2 are each independently an alkyl group having 4 to 20 carbon atoms,
R3 to R5 are each independently a group consisting of a hydrogen atom, an alkyl group having 1 to 17 carbon atoms, an aryl group having 6 to 17 carbon atoms, and a heteroaryl group having 3 to 15 carbon atoms containing at least one heteroatom. Any one atom or group selected.
However, a compound in which R1 and R2 are both butyl groups and R3 to R5 are all hydrogen atoms is excluded. ]

  The imidazole compound of the present invention is, for example, a curing agent or a curing catalyst for curing a thermosetting compound such as an epoxy compound or an episulfide compound, particularly a curing for curing a thermosetting resin such as an epoxy resin or an episulfide resin. It is useful as an agent, a curing catalyst, a urethane curing catalyst, a urethane foaming catalyst, an organic reaction catalyst, a polymer reaction catalyst, a pharmaceutical intermediate, an agrochemical intermediate, a rust inhibitor, and the like. When the imidazole compound of the present invention is used as a curing agent or a curing catalyst, the imidazole compound of the present invention has good curability and has higher storage stability than conventional imidazole curing agents and curing catalysts. Even when used as a one-component curing agent, storage stability can be improved. Furthermore, the imidazole compounds of the present invention are usually liquid in the normal state, do not require a dissolving operation, and are excellent in uniform mixing properties, so that they are easy to handle.

1 is a ¹ H-NMR spectrum of bis (2-isopropyl-5-methylhexyl) 2-imidazol-1-ylsuccinate obtained by Synthesis Example 1. FIG. FIG. 2 is a ¹ H-NMR spectrum of dibutyl 2- (2-methylimidazol-1-yl) succinate obtained by Synthesis Example 2. 3 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-methylimidazol-1-yl) succinate obtained in Synthesis Example 3. FIG. 4 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-undecylimidazol-1-yl) succinate obtained in Synthesis Example 4. FIG. 5 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-ethyl-4-methylimidazol-1-yl) succinate obtained in Synthesis Example 5. FIG. 6 is a ¹ H-NMR spectrum of 2- (2-ethyl-4-methylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) obtained by Synthesis Example 6. FIG. FIG. 7 is a ¹ H-NMR spectrum of dibutyl 2- (2-phenylimidazol-1-yl) succinate obtained by Synthesis Example 7. FIG. 8 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-phenylimidazol-1-yl) succinate obtained by Synthesis Example 8. FIG. 9 is a ¹ H-NMR spectrum of dibutyl 2- (4-phenylimidazol-1-yl) succinate obtained by Synthesis Example 9. FIG. 10 is a ¹ H-NMR spectrum of 2- (4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) obtained by Synthesis Example 10. FIG. 11 is a ¹ H-NMR spectrum of 2- (4-phenylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) obtained by Synthesis Example 11. FIG. 12 is a ¹ H-NMR spectrum of dibutyl 2- (4-methyl-2-phenylimidazol-1-yl) succinate obtained by Synthesis Example 12. 13 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-methyl-4-phenylimidazol-1-yl) succinate obtained in Synthesis Example 13. FIG. 14 is a ¹ H-NMR spectrum of dibutyl 2- (2,4-diphenylimidazol-1-yl) succinate obtained by Synthesis Example 14. FIG. FIG. 15 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2,4-diphenylimidazol-1-yl) succinate obtained by Synthesis Example 15. 16 is a ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (4,5-diphenylimidazol-1-yl) succinate obtained by Synthesis Example 16. FIG.

  The present invention will be described in detail below, but these show examples of desirable embodiments.

The imidazole compound of the present invention is an imidazole compound represented by the following general formula (I).

In the formula, R 1 and R 2 are each independently an alkyl group having 4 to 20 carbon atoms.
The alkyl group having 4 to 20 carbon atoms in R1 and R2 is a chain or branched alkyl group, for example, a butyl group, an isobutyl group, a pentyl group, a hexyl group, a 2-ethylhexyl group, an octyl group, a decyl group, Examples include 2-isopropyl-5-methylhexyl group, undecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group, nonadecyl group, icosyl group and the like. As carbon number of an alkyl group, Preferably it is C4-C18, More preferably, it is 4-15.
The alkyl group may have a substituent, and examples of the substituent include a halogen atom, a hydroxyl group, a cyano group, an alkoxy group, an ester group, an alkylcarbonyl group, an alkylcarbonyloxy group, a glycidyloxy group, and an oxetanylmethyloxy group. Group, amino group, sulfanyl group, aryl group, heteroaryl group and the like.
R1 and R2 are preferably alkyl groups having the same carbon number from the viewpoint of easy availability of raw materials and easy synthesis and low cost.

R3 to R5 are each independently a group consisting of a hydrogen atom, an alkyl group having 1 to 17 carbon atoms, an aryl group having 6 to 17 carbon atoms, and a heteroaryl group having 3 to 15 carbon atoms containing at least one heteroatom. Any one atom or group selected.
The alkyl group having 1 to 17 carbon atoms in R3 to R5 is a chain or branched alkyl group, for example, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, pentyl group, decyl group. , Undecyl group, tridecyl group, tetradecyl group, pentadecyl group, heptadecyl group and the like. As carbon number of an alkyl group, Preferably it is C1-C16, More preferably, it is 1-15.
Examples of the aryl group having 6 to 17 carbon atoms in R3 to R5 include a phenyl group, o-tolyl group, m-tolyl group, p-tolyl group, 2,3-xylyl group, 2,4-xylyl group, 2 , 5-xylyl group, 2,6-xylyl group, 3,4-xylyl group, 3,5-xylyl group, 2,4,6-mesityl group, 2-methoxyphenyl group, 3-methoxyphenyl group, 4- Methoxyphenyl group, 2,3-dimethoxyphenyl group, 2,4-dimethoxyphenyl group, 2,5-dimethoxyphenyl group, 2,6-dimethoxyphenyl group, 3,4-dimethoxyphenyl group, 3,5-dimethoxyphenyl Group, 2,3,4-trimethoxyphenyl group, 2,4,5-trimethoxyphenyl group, 2,4,6-trimethoxyphenyl group, 3,4,5-trimethoxyphenyl group, 2-hydro Siphenyl group, 3-hydroxyphenyl group, 4-hydroxyphenyl group, 2-hydroxy-3-methoxyphenyl group, 2-hydroxy-4-methoxyphenyl group, 2-hydroxy-5-methoxyphenyl group, 2,3-dihydroxy Phenyl group, 2,4-dihydroxyphenyl group, 2,5-dihydroxyphenyl group, 3,4-dihydroxyphenyl group, 3-phenoxyphenyl group, 4-phenoxyphenyl group, 4-t-butylphenyl group, 4-dimethyl Aminophenyl group, 4-diethylaminophenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 2-bromophenyl group, 3-bromophenyl group, 4-bromophenyl group, 2-chlorophenyl group , 3-chlorophenyl group, 4-chlorophenyl group, naphthyl 1-hydroxy naphthyl group, 2-hydroxy-naphthyl group, 1-bromonaphthyl group, anthracenyl group and the like. The aryl group preferably has 6 to 16 carbon atoms, and more preferably 6 to 15 carbon atoms.
Examples of the hetero atom contained in at least one heteroaryl group in R3 to R5 include a nitrogen atom, an oxygen atom, a sulfur atom, etc., and a heteroaryl group having 3 to 15 carbon atoms containing at least one such heteroatom. Examples thereof include a furanyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a pyridyl group, a carbazolyl group, an indolyl group, a benzofuranyl group, a chromenyl group, and an isochromenyl group.
The alkyl group having 1 to 17 carbon atoms, the aryl group having 6 to 17 carbon atoms, and the heteroaryl group having 3 to 15 carbon atoms containing at least one heteroatom may have a substituent. Examples thereof include a halogen atom, a nitro group, an alkyl group, a hydroxyl group, an alkoxy group, an amino group, a sulfanyl group, an aryl group, and a heteroaryl group.

  The imidazole compound of the present invention excludes compounds in which R1 and R2 are both butyl groups and R3 to R5 are all hydrogen atoms in the above general formula (I).

Specific examples of the imidazole compound of the present invention include, for example, 2-imidazol-1-ylsuccinic acid bis (2-isopropyl-5-methylhexyl), 2- (4-phenylimidazol-1-yl) succinic acid. Acid bis (2-isopropyl-5-methylhexyl), 2- (4- (2-hydroxyphenyl) imidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl), 2- (2-hydroxy Phenyl) imidazol-1-ylsuccinic acid bis (2-isopropyl-5-methylhexyl), 2- (2-hydroxy-3-methoxyphenyl) imidazol-1-ylsuccinic acid bis (2-isopropyl-5-methylhexyl) ), 2- (2-hydroxy-5-methoxyphenyl) imidazol-1-ylsuccinic acid bis (2-isopropyl) Pyr-5-methylhexyl), 2- (3-methoxyphenyl) imidazol-1-ylsuccinic acid bis (2-isopropyl-5-methylhexyl), 2- (2-fluorophenyl) imidazol-1-ylsuccinic acid Bis (2-isopropyl-5-methylhexyl), 2- (3-fluorophenyl) imidazol-1-yl succinic acid bis (2-isopropyl-5-methylhexyl), 2- (2-ethyl-4-methylimidazole) -1-yl) succinic acid bis (2-isopropyl-5-methylhexyl), 2- (4-methyl-2-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2-un Decylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2-phenylimidazol-1-yl) succinic acid Bis (2-ethylhexyl), 2- (4- (2-hydroxyphenyl) imidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2-hydroxyphenyl) imidazol-1-ylsuccinic acid bis ( 2-ethylhexyl), 2- (2-hydroxy-3-methoxyphenyl) imidazol-1-yl succinic acid bis (2-ethylhexyl), 2- (2-hydroxy-5-methoxyphenyl) imidazol-1-yl succinic acid Bis (2-ethylhexyl), 2- (3-methoxyphenyl) imidazol-1-ylsuccinic acid bis (2-ethylhexyl), 2- (2-fluorophenyl) imidazol-1-ylsuccinic acid bis (2-ethylhexyl) 2- (3-Fluorophenyl) imidazol-1-ylsuccinic acid bis (2-ethylhexyl) ), 2- (4,5-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2,4-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2-Ethyl-4-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (4-phenyl) Imidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (2-methyl-4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl), 2- (4-phenylimidazole-1- Yl) succinate dibutyl, 2- (4- (2-hydroxyphenyl) imidazol-1-yl) succinate dibutyl, 2- (2-hydroxypheny ) Imidazol-1-yl succinate dibutyl, 2- (2-hydroxy-3-methoxyphenyl) imidazol-1-yl succinate, 2- (2-hydroxy-5-methoxyphenyl) imidazol-1-yl succinate dibutyl, 2- (3-methoxyphenyl) imidazol-1-yl succinate dibutyl, 2- (2-fluorophenyl) imidazol-1-yl succinate dibutyl, 2- (3-fluorophenyl) imidazol-1-yl succinate dibutyl , 2- (2-methylimidazol-1-yl) succinic acid dibutyl, 2- (2,4-diphenylimidazol-1-yl) succinic acid dibutyl, 2- (2-phenylimidazol-1-yl) succinic acid dibutyl 2- (4-Methyl-2-phenylimidazol-1-yl) succinic acid dibu Le and the like.
The imidazole compound of the present invention can be produced according to known synthesis conditions.

The imidazole compound of the present invention is, for example, a curing agent or a curing catalyst for curing a thermosetting compound such as an epoxy compound or an episulfide compound, particularly a curing for curing a thermosetting resin such as an epoxy resin or an episulfide resin. It is useful as an agent, a curing catalyst, a urethane curing catalyst, a urethane foaming catalyst, an organic reaction catalyst, a polymer reaction catalyst, a pharmaceutical intermediate, an agrochemical intermediate, a rust inhibitor, and the like.
Illustratively, the case where the imidazole compound of the present invention is used as a curing agent for an anion curable compound will be described. Examples of the anion curable compound to be cured include an epoxy compound or an episulfide compound.
In the present invention, the curing agent for an anion curable compound includes not only what functions as a curing agent but also what functions as a curing accelerator (curing aid).

  The epoxy compound has an average of two or more epoxy groups in one molecule. Representative epoxy compounds include bisphenol A, bisphenol F, bisphenol E, bisphenol AD, bisphenol S, tetramethyl bisphenol A, tetramethyl bisphenol F, tetramethyl bisphenol AD, tetramethyl bisphenol S, tetrabromobisphenol A, and the like. Bisphenol-type epoxy resins obtained by glycidylation of bisphenols, epoxy resins obtained by glycidylation of other dihydric phenols such as biphenol, dihydroxynaphthalene and 9,9-bis (4-hydroxyphenyl) fluorene, 1,1,1-tris ( Trispheno such as 4-hydroxyphenyl) methane, 4,4- (1- (4- (1- (4-hydroxyphenyl) -1-methylethyl) phenyl) ethylidene) bisphenol Glycidylated epoxy resins, p-aminophenol and other aminophenols glycidylated epoxy resins, 1,1,2,2-tetrakis (4-hydroxyphenyl) ethane and other tetrakisphenols glycidylated epoxies Resin, phenol novolak, cresol novolak, bisphenol A novolak, brominated phenol novolak, novolac epoxy resin glycidylated brominated bisphenol A novolak, etc., aliphatic ether type epoxy glycidylated polyhydric alcohols such as glycerin and polyethylene glycol Resin, ether ester type epoxy resin obtained by glycidylation of hydroxycarboxylic acid such as p-oxybenzoic acid and β-oxynaphthoic acid, and polycarboxylic acid such as phthalic acid Sidylated ester type epoxy resin, glycidylated products of amine compounds such as 4,4-diaminodiphenylmethane and m-aminophenol, and amine type epoxy resins such as triglycidyl isocyanurate, 3,4-epoxycyclohexylmethyl-3 ′, 4 And alicyclic epoxides such as' -epoxycyclohexanecarboxylate. What mixed these 1 type, or 2 or more types of these epoxy compounds can be used.

  The episulfide compound is a monofunctional episulfide compound or an compound having two or more episulfide groups on average in one molecule. Representative episulfide compounds include, for example, bisphenol A, bisphenol F, bisphenol E, bisphenol AD, bisphenol S, tetramethyl bisphenol A, tetramethyl bisphenol F, tetramethyl bisphenol AD, tetramethyl bisphenol S, tetrabromobisphenol A, and the like. Bisphenol-type episulfide resin obtained by thioglycidylation of bisphenols, bisphenol A, bisphenol F, bisphenol E, bisphenol AD, bisphenol S, tetramethylbisphenol A, tetramethylbisphenol F, tetramethylbisphenol AD, tetramethylbisphenol S, tetrabromo Hydrogen obtained by thioglycidylation of nuclear hydrogenated products of bisphenols such as bisphenol A Episulfide resin obtained by thioglycidylation of other dihydric phenols such as bisphenol type episulfide resin, biphenol, dihydroxynaphthalene, dihydroxyanthracene, 9,9-bis (4-hydroxyphenyl) fluorene, 1,1,1-tris (4 Episulfide resin obtained by thioglycidylation of trisphenols such as -hydroxyphenyl) methane, 4,4- (1- (4- (1- (4-hydroxyphenyl) -1-methylethyl) phenyl) ethylidene) bisphenol, Episulfide resin obtained by thioglycidylation of tetrakisphenols such as 1,2,2,2-tetrakis (4-hydroxyphenyl) ethane, phenol novolak, cresol novolak, bisphenol A novolak, brominated phenol novolak , Novolak type episulfide resin obtained by thioglycidylation of brominated bisphenol A novolak, etc., aliphatic ether type episulfide resin obtained by thioglycidylation of polyhydric alcohol such as glycerin and polyethylene glycol, p-oxybenzoic acid, β-oxynaphthoic acid, etc. Ether-type episulfide resin obtained by thioglycidylation of hydroxycarboxylic acid, ester-type episulfide resin obtained by thioglycidylation of polycarboxylic acid such as phthalic acid and terephthalic acid, amines such as 4,4-diaminodiphenylmethane and m-aminophenol Amine-type episulfide resins such as thioglycidyl compounds of compounds and triglycidyl isocyanurate, polyalkylene polyamines such as diethylenetriamine and triethylenetetramine, and dications such as adipic acid Polyglycolamine thioglycidylates with bonic acid, 3,4-epithiocyclohexylmethyl-3 ′, 4′-epithiocyclohexanecarboxylate, bis- (3,4-epithiocyclohexyl) adipate, 1,2-epithio Cycloaliphatic episulfides such as -4-vinylcyclohexane, silicone-modified episulfide resins obtained by reaction of organopolysiloxanes with episulfide resins or phenol novolac-type episulfide resins, thioglycidyl methacrylate, 3,4-epithiocyclohexylmethyl methacrylate, propylene Episulfide compounds such as sulfide and cyclohexane sulfide and polymers thereof, bis (2,3-epithiopropyl) sulfide, bis (2,3-epithiopropylthio) ethane, bis (5, - epithio-3 Chiohekisan) episulfide compound of the sulfides and the like. A mixture of one or more of these episulfide compounds can be used.

  The epoxy compound and the episulfide compound may be used in combination.

  The imidazole compound of the present invention as a curing agent for an anion curable compound is usually 0.1 to 50 parts by weight, preferably 0.2 to 45 parts by weight, particularly preferably 100 parts by weight of an anion curable compound. 0.3 to 40 parts by weight can be used.

  A plurality of imidazole compounds of the present invention can be used in combination for the purpose of adjusting curability and storage stability.

  The imidazole compound of the present invention as a curing agent for an anion curable compound can be used alone, or amines, polyamines, hydrazines, acid anhydrides, dicyandiamide, onium salts, polythiols, phenols, ketimines It can also be used in combination with a generally used curing agent such as. Further, it can be used in combination with a known or general curing accelerator (curing aid) for an anion curable compound. In addition, the imidazole compound of the present invention can be used in combination with the above-mentioned known general curing agent to catalytically promote the curing performance.

  As a method for mixing the imidazole compound and the anion curable compound of the present invention, for example, a curable composition containing a predetermined amount of the imidazole compound and the anion curable compound is mixed with a roll kneader, a kneader, a mixer or an extruder. Etc. are kneaded. Then, the cured product of the anion curable compound can be obtained by heating the curable composition after kneading. As the heating conditions, the heating temperature and the heating time can be appropriately selected in consideration of the type of anion curable compound, the type of curing agent, the type of additive, the blending amount of each component, and the like.

  The curable composition containing the imidazole compound of the present invention as a curing agent for an anion curable compound has high storage stability, and the cured product has properties such as heat resistance, dimensional stability, and adhesiveness. From the above, the imidazole compound of the present invention includes, for example, conductive adhesives, adhesives for relays, adhesives for chip parts, liquid sealants for electronic members such as adhesive sheets, adhesive films, semiconductors, and the like. Component of electronic materials such as conductive paste, insulating paste, underfill material, prepreg, insulating varnish, impregnating varnish, paint or printing ink, organic EL and LED sealing sealant and adhesive, color filter, organic Light extraction layer and light extraction film such as EL, display substrate, flexible display substrate, flexible display film, semiconductor device , An electronic component, an interlayer insulating film, the wiring covering film, an optical circuit, an optical circuit component, the anti-reflection film, can be widely used as a component of an optical member or building materials holograms. Thus, for example, printed circuit boards, printed wiring boards, relay materials, semiconductor devices, various parts such as automobiles and aircraft, printed materials, transparent sealants, color filters, display substrates, display films, semiconductor devices, electronic components, interlayers An insulating film, a wiring coating film, an optical circuit, an optical circuit component, an antireflection film, an electronic member such as a hologram, an optical member, a building member, or the like is provided. Moreover, the pattern etc. formed as hardened | cured material are equipped with heat resistance and insulation, for example, transparent sealing agent, a color filter, a display substrate, a flexible display substrate, a film for flexible displays, an electronic component, a semiconductor device, interlayer insulation It can be advantageously used as a film, a wiring coating film, an optical circuit, an optical circuit component, an antireflection film, other optical members or electronic members.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated further more concretely, this invention is not limited to a following example, unless the summary is exceeded.

[Synthesis Example 1: Synthesis of bis (2-isopropyl-5-methylhexyl) 2-imidazol-1-ylsuccinate]
A 100 mL four-necked flask was charged with 3.8 g (0.03 mol) of diazabicycloundecene (DBU), 20 mL of acetonitrile, and 3.8 g (0.06 mol) of imidazole, and stirred at 25 ° C. Thereto, 20.0 g (0.05 mol) of bis (2-isopropyl-5-methylhexyl) fumarate was added dropwise and reacted at 25 ° C. for 2 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, followed by extraction with 60 mL of methylene chloride and 40 mL of water. The separated organic layer was concentrated, and the obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 2/3) to give liquid 2-imidazol-1-yl succinate (2-isopropyl). -5-methylhexyl) was obtained. The obtained 2-imidazol-1-ylsuccinic acid bis (2-isopropyl-5-methylhexyl) was 9.4 g and the yield was 40%.
2-Imidazol-1-ylsuccinic acid bis (2-isopropyl-5-methylhexyl)
, The elimination reaction of the protecting group started under the temperature condition of 259 ° C., and bis (2-isopropyl-5-succinate) in bis (2-isopropyl-5-methylhexyl) -2-imidazol-1-ylsuccinate. It was confirmed by NMR analysis that -methylhexyl) was eliminated.

¹ H-NMR spectrum of bis (2-isopropyl-5-methylhexyl) 2-imidazol-1-ylsuccinate obtained by Synthesis Example 1 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetra Methoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 1, and its attribution is as follows.
7.56 ppm (s, 1H, Ar-H)
7.06 ppm (s, 1H, Ar-H)
6.97 ppm (d, 1H, Ar-H)
5.22 ppm (t, 1H, —CO—CH—)
3.99-4.18ppm (m, 4H, -CO- OCH 2 -)
3.25 ppm (dd, 1H, —CO—CH ₂ —)
2.97 ppm (dd, 1H, —CO—CH ₂ —)
1.63-1.72 ppm (m, 2H, -CH-)
1.09-1.50 ppm (m, 12H, —CH—, —CH ₂ —)
_{0.81-0.91ppm (m, 24H, -CH 3} )

[Synthesis Example 2: Synthesis of 2- (2-methylimidazol-1-yl) succinate dibutyl]
A 100 mL four-necked flask was charged with 20.0 g (0.09 mol) of dibutyl fumarate, 30 mL of acetonitrile, and 14.4 g (0.18 mol) of 2-methylimidazole and stirred at 25 ° C. DBU4.0g (0.03mol) was dripped there and it was made to react at 25 degreeC for 4 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-methylimidazol-1-yl) succinate. The obtained 2- (2-methylimidazol-1-yl) succinic acid dibutyl was 9.1 g and the yield was 44%.
2- (2-Methylimidazol-1-yl) succinate dibutyl dibutyl 2- (2-methylimidazol-1-yl) succinate was initiated under the temperature condition of 199 ° C. It was confirmed by NMR analysis that dibutyl succinate was eliminated.

The ¹ H-NMR spectrum of dibutyl 2- (2-methylimidazol-1-yl) succinate obtained by Synthesis Example 2 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetramethoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 2, and its attribution is as follows.
6.93 ppm (d, 1H, Ar-H)
6.85 ppm (d, 1H, Ar-H)
5.18 ppm (t, 1H, —CO—CH—)
4.14 ppm (t, 2H, —CO—OCH ₂ —)
4.08 ppm (t, 2H, —CO—OCH ₂ —)
3.25 ppm (dd, 1H, —CO—CH ₂ —)
2.91 ppm (dd, 1H, —CO—CH ₂ —)
_{2.45ppm (s, 3H, -CH 3} )
1.53-1.61 ppm (m, 4H, —CH ₂ —)
_{1.26-1.36ppm (m, 4H, -CH 2} -)
_{0.91ppm (t, 3H, -CH 3} )
_{0.89ppm (t, 3H, -CH 3} )

[Synthesis Example 3: Synthesis of 2- (2-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl)]
A 200 mL four-necked flask was charged with 20.0 g (0.06 mol) of bis (2-ethylhexyl) fumarate, 30 mL of acetonitrile, and 9.6 g of 2-methylimidazole (0.12 mol), and stirred at 25 ° C. DBU2.68g (0.02mol) was dripped there and it was made to react at 25 degreeC for 18 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl). . The obtained 2- (2-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 18.5 g, and the yield was 75%.
In 2- (2-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl), the elimination reaction of the protecting group started under the temperature condition of 251 ° C., and 2- (2-methylimidazol-1-yl It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in bis (2-ethylhexyl) succinate was eliminated.

The ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-methylimidazol-1-yl) succinate obtained in Synthesis Example 3 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetra Methoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 3, and the attribution is as follows.
6.92 ppm (d, 1H, Ar-H)
6.85 ppm (d, 1H, Ar-H)
5.20 ppm (t, 1H, —CO—CH—)
3.96-4.11 ppm (m, 4H, —CO—OCH ₂ —)
3.27 ppm (dd, 1H, —CO—CH ₂ —)
2.93 ppm (dd, 1H, —CO—CH ₂ —)
_{2.45ppm (s, 3H, -CH 3} )
1.18-1.54 ppm (m, 18H, —CH—, —CH ₂ —)
_{0.80-0.91ppm (m, 12H, -CH 3} )

[Synthesis Example 4: Synthesis of 2- (2-undecylimidazol-1-yl) succinic acid bis (2-ethylhexyl)]
A 200 mL four-necked flask was charged with 20.0 g (0.06 mol) of bis (2-ethylhexyl) fumarate, 30 mL of acetonitrile, and 19.6 g (0.09 mol) of 2-undecylimidazole, and stirred at 25 ° C. DBU2.7g (0.02 mol) was dripped there and it was made to react at 25 degreeC for 22 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid is purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-undecylimidazol-1-yl) succinic acid bis (2-ethylhexyl). did. The obtained 2- (2-undecylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 11.0 g, and the yield was 33%.
2- (2-Undecylimidazol-1-yl) succinic acid bis (2-ethylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 280 ° C., and 2- (2-undecylimidazole-1 It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in -yl) succinic acid bis (2-ethylhexyl) was eliminated.

The ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-undecylimidazol-1-yl) succinate obtained in Synthesis Example 4 (using “Ascend 400” manufactured by Bruker, internal standard substance: Tetramethoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 4, and the attribution is as follows.
6.95 ppm (d, 1H, Ar-H)
6.83 ppm (d, 1H, Ar-H)
5.22 ppm (t, 1H, —CO—CH—)
3.96-4.11 ppm (m, 4H, —CO—OCH ₂ —)
3.27 ppm (dd, 1H, —COCH ₂ —)
2.89 ppm (dd, 1H, —COCH ₂ —)
2.72 ppm (m, 2H, —CH ₂ —)
1.73-1.79 ppm (m, 2H, —CH ₂ —)
1.49-1.55 ppm (m, 2H, -CH-)
1.16 to 1.40 ppm (m, 32H, —CH ₂ —)
_{0.80-0.91ppm (m, 15H, -CH 3} )

[Synthesis Example 5: Synthesis of bis (2-ethylhexyl) 2- (2-ethyl-4-methylimidazol-1-yl) succinate]
A 200 mL four-necked flask is charged with 20.0 g (0.06 mol) of bis (2-ethylhexyl) fumarate, 30 mL of acetonitrile, and 12.9 g (0.12 mol) of 2-ethyl-4-methylimidazole, and stirred at 25 ° C. did. DBU2.7g (0.02 mol) was dripped there, and it was made to react at 25 degreeC for 24 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-ethyl-4-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl). ). The obtained 2- (2-ethyl-4-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 20.65 g, and the yield was 78%.
2- (2-Ethyl-4-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 246 ° C., and 2- (2-ethyl- It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in 4-methylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was eliminated.

The ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-ethyl-4-methylimidazol-1-yl) succinate obtained by Synthesis Example 5 (using “Ascend 400” manufactured by Bruker, internal Reference substance: tetramethoxysilane, solvent: CDCl ₃ ) are as shown in FIG. 5 and their attribution is as follows.
6.54 ppm (s, 1H, Ar-H)
5.15 ppm (t, 1H, —CO—CH—)
3.99-4.11 ppm (m, 4H, —CO—OCH ₂ —)
3.24 ppm (dd, 1H, —CO—CH ₂ —)
2.92 ppm (dd, 1H, —CO—CH ₂ —)
2.73 ppm (q, 2H, —CH ₂ —)
_{2.15ppm (s, 3H, -CH 3} )
1.50-1.54 ppm (m, 2H, -CH-)
1.16 to 1.35 ppm (m, 19H, —CH ₂ —, —CH ₃ )
_{0.87-0.91ppm (m, 12H, -CH 3} )

[Synthesis Example 6: Synthesis of bis (2-isopropyl-5-methylhexyl) 2- (2-ethyl-4-methylimidazol-1-yl) succinate]
A 50 mL four-necked flask was charged with 1.5 g (0.01 mol) of DBU, 10 mL of acetonitrile, and 2.2 g (0.02 mol) of 2-ethyl-4-methylimidazole, and stirred at 25 ° C. Thereto, 8.0 g (0.02 mol) of bis (2-isopropyl-5-methylhexyl) fumarate was added dropwise and reacted at 25 ° C. for 20 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, followed by extraction with 30 mL of methylene chloride and 20 mL of water. The separated organic layer was concentrated, and the obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 2/3) to obtain liquid 2- (2-ethyl-4-methylimidazole-1- Yl) succinic acid bis (2-isopropyl-5-methylhexyl) was obtained. The obtained 2- (2-ethyl-4-methylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) was 5.5 g and the yield was 54%.
2- (2-Ethyl-4-methylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) starts a protecting group elimination reaction at a temperature of 284 ° C. NMR analysis that bis (2-isopropyl-5-methylhexyl) succinate in (2-ethyl-4-methylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) is eliminated. It was possible to confirm.

The ¹ H-NMR spectrum of bis (2-isopropyl-5-methylhexyl) 2- (2-ethyl-4-methylimidazol-1-yl) succinate obtained by Synthesis Example 6 (“Bruker” Ascend 400 ”, internal standard substance: tetramethoxysilane, solvent: CDCl ₃ ) are as shown in FIG. 6 and their assignments are as follows.
6.53 ppm (s, 1 H, Ar—H)
5.14 ppm (t, 1H, —CO—CH—)
3.98-4.16 ppm (m, 4H, —CO—OCH ₂ —)
3.23 ppm (dd, 1H, —CO—CH ₂ —)
2.85 ppm (dd, 1H, —CO—CH ₂ —)
2.73 ppm (q, 2H, —CH ₂ —)
_{2.15ppm (s, 3H, -CH 3} )
1.07-1.71ppm (m, 17H, -CH - , - CH 2 -, - CH 3)
_{0.79-0.89ppm (m, 24H, -CH 3} )

[Synthesis Example 7: Synthesis of 2- (2-phenylimidazol-1-yl) succinate dibutyl]
A 200 mL four-necked flask was charged with 30.0 g (0.13 mol) of dibutyl fumarate, 45 mL of acetonitrile, and 36.8 g (0.26 mol) of 2-phenylimidazole, and stirred at 25 ° C. DBU6.0g (0.04mol) was dripped there, and it was made to react at 25 degreeC for 24 hours. After completion of the reaction, extraction was performed with 30 mL of ethyl acetate and 120 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-phenylimidazol-1-yl) succinate. The obtained 2- (2-phenylimidazol-1-yl) succinic acid dibutyl was 12.2 g and the yield was 25%.
In 2- (2-phenylimidazol-1-yl) succinate, dibutyl 2- (2-phenylimidazol-1-yl) succinate starts the elimination reaction of the protecting group under the temperature condition of 236 ° C. It was confirmed by NMR analysis that dibutyl succinate was eliminated.

The ¹ H-NMR spectrum of dibutyl 2- (2-phenylimidazol-1-yl) succinate obtained by Synthesis Example 7 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetramethoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 7, and its attribution is as follows.
7.62-7.64 ppm (m, 2H, Ar-H)
7.45-7.47 ppm (m, 3H, Ar-H)
7.17 ppm (d, 1H, N—C (H) = C)
7.08 ppm (d, 1H, N—C (H) = C)
5.44 ppm (t, 1H, —CO—CH—)
4.16 ppm (dt, 2H, —CO—OCH ₂ —)
4.02 ppm (dt, 2H, —CO—OCH ₂ —)
3.21 ppm (dd, 1H, —CO—CH ₂ —)
2.95 ppm (dd, 1H, —CO—CH ₂ —)
1.50-1.59 ppm (m, 4H, —CH ₂ —)
1.2-1.32 ppm (m, 4H, —CH ₂ —)
_{0.89ppm (t, 6H, -CH 3} )

[Synthesis Example 8: Synthesis of bis (2-ethylhexyl) 2- (2-phenylimidazol-1-yl) succinate]
A 200 mL four-necked flask was charged with 20.0 g (0.06 mol) of bis (2-ethylhexyl) fumarate, 30 mL of acetonitrile, and 16.5 g (0.12 mol) of 2-phenylimidazole, and stirred at 25 ° C. DBU2.68g (0.02mol) was dripped there, and it was made to react at 25 degreeC for 24 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl). . The obtained 2- (2-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 6.0 g and the yield was 21%.
2- (2-Phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 255 ° C., and 2- (2-phenylimidazol-1-yl It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in bis (2-ethylhexyl) succinate was eliminated.

In addition, ¹ H-NMR spectrum of 2- (2-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) obtained in Synthesis Example 8 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetra Methoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 8, and the attribution is as follows.
7.63-7.65 ppm (m, 2H, Ar-H)
7.44-7.48 ppm (m, 3H, Ar-H)
7.16 ppm (d, 1H, Ar-H)
7.06 ppm (d, 1H, Ar-H)
5.46 ppm (t, 1H, —CO—CH—)
3.91-4.14ppm (m, 4H, -CO- OCH 2 -)
3.24 ppm (dd, 1H, —CO—CH ₂ —)
2.95 ppm (dd, 1H, —CO—CH ₂ —)
1.48-1.52 ppm (m, 2H, -CH-)
1.18-1.30 ppm (m, 16H, —CH ₂ —)
_{0.80-0.90ppm (m, 12H, -CH 3} )

[Synthesis Example 9: Synthesis of 2- (4-phenylimidazol-1-yl) succinate dibutyl]
In a 100 mL four-necked flask, 5.0 g (0.03 mol) of DBU, 15 mL of acetonitrile, and 9.5 g (0.06 mol) of 4-phenylimidazole were charged and stirred at 25 ° C. Thereto, 15.0 g (0.07 mol) of dibutyl fumarate was added dropwise and reacted at 25 ° C. for 30 minutes. After completion of the reaction, the solvent was distilled off under reduced pressure, followed by extraction with 60 mL of methylene chloride and 40 mL of water. The collected organic layer is concentrated, and the obtained concentrated liquid is purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (4-phenylimidazol-1-yl) succinic acid. Dibutyl was acquired. The obtained 2- (4-phenylimidazol-1-yl) succinic acid dibutyl was 12.6 g and the yield was 51%.
2- (4-Phenylimidazol-1-yl) succinic acid dibutyl has a protecting group elimination reaction under a temperature condition of 254 ° C., and 2- (4-phenylimidazol-1-yl) succinic acid dibutyl Desorption was confirmed by NMR analysis.

¹ H-NMR spectrum of dibutyl 2- (4-phenylimidazol-1-yl) succinate obtained by Synthesis Example 9 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetramethoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 9, and its attribution is as follows.
7.75-7.77 ppm (m, 2H, Ar-H)
7.61 ppm (d, 1H, Ar-H)
7.35-7.39 ppm (m, 2H, Ar-H)
7.22-7.28 ppm (m, 2H, Ar-H)
5.22 ppm (t, 1H, —CO—CH—)
4.18 ppm (dt, 2H, —CO—OCH ₂ —)
4.09 ppm (t, 2H, —CO—OCH ₂ —)
3.28 ppm (dd, 1H, —CO—CH ₂ —)
3.02 ppm (dd, 1H, —CO—CH ₂ —)
1.54-1.64 ppm (m, 4H, —CH ₂ —)
1.27-1.37 ppm (m, 4H, —CH ₂ —)
_{0.90ppm (t, 3H, -CH 3} )
_{0.89ppm (t, 3H, -CH 3} )

Synthesis Example 10 Synthesis of 2- (4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl)
A 100 mL four-necked flask was charged with 2.6 g (0.02 mol) of DBU, 15 mL of acetonitrile, and 5.0 g (0.04 mol) of 4-phenylimidazole, and stirred at 25 ° C. Thereto, 11.8 g (0.04 mol) of bis (2-ethylhexyl) fumarate was added dropwise and reacted at 25 ° C. for 30 minutes. After completion of the reaction, the solvent was distilled off under reduced pressure, followed by extraction with 60 mL of methylene chloride and 40 mL of water. The collected organic layer is concentrated, and the obtained concentrated liquid is purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (4-phenylimidazol-1-yl) succinic acid. Bis (2-ethylhexyl) was obtained. The obtained 2- (4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 10.8 g and the yield was 64%.
2- (4-Phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 287 ° C., and 2- (4-phenylimidazol-1-yl It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in bis (2-ethylhexyl) succinate was eliminated.

In addition, ¹ H-NMR spectrum of 2- (4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) obtained by Synthesis Example 10 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetra Methoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 10, and the attribution is as follows.
7.74-7.76 ppm (m, 2H, Ar-H)
7.61 ppm (d, 1H, Ar-H)
7.34-7.38 ppm (m, 2H, Ar-H)
7.22-7.27 ppm (m, 2H, Ar-H)
5.24 ppm (t, 1H, —CO—CH—)
3.97-4.15 ppm (m, 4H, —CO—OCH ₂ —)
3.30 ppm (dd, 1H, —CO—CH ₂ —)
3.03 ppm (dd, 1H, —CO—CH ₂ —)
1.50-1.56 ppm (m, 2H, -CH-)
1.20-1.34 ppm (m, 16H, —CH ₂ —)
0.81-0.91 ppm (m, 12H, —CH ₃ )

[Synthesis Example 11: Synthesis of bis (2-isopropyl-5-methylhexyl) 2- (4-phenylimidazol-1-yl) succinate]
A 50 mL four-necked flask was charged with 1.7 g (0.01 mol) of DBU, 10 mL of acetonitrile and 3.3 g (0.02 mol) of 4-phenylimidazole, and stirred at 25 ° C. Thereto, 9.0 g (0.02 mol) of bis (2-isopropyl-5-methylhexyl) fumarate was added dropwise and reacted at 25 ° C. for 30 minutes. After completion of the reaction, the solvent was distilled off under reduced pressure, followed by extraction with 30 mL of methylene chloride and 20 mL of water. The collected organic layer is concentrated, and the obtained concentrated liquid is purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (4-phenylimidazol-1-yl) succinic acid. Bis (2-isopropyl-5-methylhexyl) was obtained. The obtained 2- (4-phenylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) was 6.9 g, and the yield was 56%.
2- (4-Phenylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 292 ° C. It was confirmed by NMR analysis that bis (2-isopropyl-5-methylhexyl) succinate in imidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) was eliminated.

The ¹ H-NMR spectrum of 2- (4-phenylimidazol-1-yl) succinic acid bis (2-isopropyl-5-methylhexyl) obtained by Synthesis Example 11 (using “Ascend 400” manufactured by Bruker) The internal standard substance: tetramethoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 11, and the attribution is as follows.
7.73-7.76 ppm (m, 2H, Ar-H)
7.60 ppm (d, 1H, Ar-H)
7.34-7.38 ppm (m, 2H, Ar-H)
7.22-7.27 ppm (m, 2H, Ar-H)
5.22 ppm (t, 1H, —CO—CH—)
4.00-4.20 ppm (m, 4H, —CO—OCH ₂ —)
3.29 ppm (dd, 1H, —CO—CH ₂ —)
3.02 ppm (dd, 1H, —CO—CH ₂ —)
1.63-1.73 ppm (m, 2H, -CH-)
1.07-1.49 ppm (m, 12H, —CH—, —CH ₂ —)
_{0.81-0.91ppm (m, 24H, -CH 3} )

[Synthesis Example 12: Synthesis of 2- (4-methyl-2-phenylimidazol-1-yl) succinate dibutyl]
A 200 mL four-necked flask was charged with 30.0 g (0.13 mol) of dibutyl fumarate, 45 mL of acetonitrile, and 41.6 g (0.26 mol) of 4-methyl-2-phenylimidazole, and stirred at 25 ° C. DBU6.0g (0.04mol) was dripped there, and it was made to react at 25 degreeC for 24 hours. After completion of the reaction, extraction was performed with 30 mL of ethyl acetate and 120 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (4-methyl-2-phenylimidazol-1-yl) succinate. The obtained 2- (4-methyl-2-phenylimidazol-1-yl) succinic acid dibutyl was 16.3 g and the yield was 32%.
The dibutyl 2- (4-methyl-2-phenylimidazol-1-yl) succinate starts the elimination reaction of the protecting group under the temperature condition of 208 ° C., and 2- (4-methyl-2-phenylimidazole- It was confirmed by NMR analysis that dibutyl succinate in 1-yl) dibutyl succinate was eliminated.

The ¹ H-NMR spectrum of dibutyl 2- (4-methyl-2-phenylimidazol-1-yl) succinate obtained in Synthesis Example 12 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetramethoxy) Silane, solvent: CDCl ₃ ) is as shown in FIG. 12, and its attribution is as follows.
7.60-7.63 ppm (m, 2H, Ar-H)
7.42-7.58 ppm (m, 3H, Ar-H)
6.77 ppm (d, 1H, Ar-H)
5.37 ppm (t, 1H, —CO—CH—)
5.15 ppm (dt, 2H, —CO—OCH ₂ —)
4.05ppm (dt, 2H, -CO- OCH 2 -)
3.21 ppm (dd, 1H, —CO—CH ₂ —)
2.89 ppm (dd, 1H, —CO—CH ₂ —)
2.25 ppm (s, 3H, -CH3)
1.49-1.60 ppm (m, 4H, —CH ₂ —)
1.25-1.34 ppm (m, 4H, —CH ₂ —)
_{0.90ppm (t, 3H, -CH 3} )
_{0.89ppm (t, 3H, -CH 3} )

[Synthesis Example 13: Synthesis of bis (2-ethylhexyl) 2- (4-methyl-2-phenylimidazol-1-yl) succinate]
A 200 mL four-necked flask is charged with 20.0 g (0.06 mol) of bis (2-ethylhexyl) fumarate, 30 mL of acetonitrile, and 18.6 g (0.11 mol) of 4-methyl-2-phenylimidazole, and stirred at 25 ° C. did. DBU2.7g (0.02 mol) was dripped there, and it was made to react at 25 degreeC for 24 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2-methyl-4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl). ). The obtained 2- (2-methyl-4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 8.2 g and the yield was 28%.
2- (2-Methyl-4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 269 ° C., and 2- (2-methyl- It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in 4-phenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was eliminated.

The ¹ H-NMR spectrum of bis (2-ethylhexyl) 2- (2-methyl-4-phenylimidazol-1-yl) succinate obtained in Synthesis Example 13 (using “Ascend 400” manufactured by Bruker, internal Standard substance: tetramethoxysilane, solvent: CDCl ₃ ) are as shown in FIG. 13 and their attribution is as follows.
7.61-7.64 ppm (m, 2H, Ar-H)
7.40-7.47 ppm (m, 3H, Ar-H)
6.76 ppm (d, 1H, Ar-H)
5.39 ppm (t, 1H, —CO—CH—)
3.91-4.14ppm (m, 4H, -CO- OCH 2 -)
3.23 ppm (dd, 1H, —CH ₂ —)
2.89 ppm (dd, 1H, —CH ₂ —)
2.25 ppm (s, 3H, —CH ₃ )
1.49-1.53 ppm (m, 2H, -CH-)
1.17-1.32 ppm (m, 16H, —CH ₂ —)
0.81-0.91 ppm (m, 12H, —CH ₃ )

[Synthesis Example 14: Synthesis of 2- (2,4-diphenylimidazol-1-yl) succinate dibutyl]
A 200 mL four-necked flask was charged with 29.9 g (0.13 mol) of dibutyl fumarate, 45 mL of acetonitrile, and 43.3 g (0.20 mol) of 2,4-diphenylimidazole, and stirred at 25 ° C. DBU6.0g (0.04mol) was dripped there and it was made to react at 25 degreeC for 20 hours. After completion of the reaction, extraction was performed with 30 mL of ethyl acetate and 120 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2,4-diphenylimidazol-1-yl) succinate. The obtained 2- (2,4-diphenylimidazol-1-yl) succinic acid dibutyl was 12.0 g and the yield was 20%.
In 2- (2,4-diphenylimidazol-1-yl) succinate, the elimination reaction of the protecting group starts under the temperature condition of 266 ° C., and 2- (2,4-diphenylimidazol-1-yl) It was confirmed by NMR analysis that dibutyl succinate was eliminated from dibutyl succinate.

The ¹ H-NMR spectrum of dibutyl 2- (2,4-diphenylimidazol-1-yl) succinate obtained in Synthesis Example 14 (using “Ascend 400” manufactured by Bruker, internal standard substance: tetramethoxysilane, The solvent: CDCl ₃ ) is as shown in FIG. 14, and the attribution is as follows.
7.82-7.84 ppm (m, 2H, Ar-H)
7.67-7.70 ppm (m, 2H, Ar-H)
7.48-7.50 ppm (m, 3H, Ar-H)
7.35-7.39 ppm (m, 3H, Ar-H)
7.22-7.27 ppm (m, 1H, Ar-H)
5.41 ppm (t, 1H, —CO—CH—)
4.18 ppm (t, 2H, —CO—OCH ₂ —)
4.05ppm (dt, 2H, -CO- OCH 2 -)
3.25 ppm (dd, 1H, —CO—CH ₂ —)
2.99 ppm (dd, 1H, —CO—CH ₂ —)
1.49-1.65 ppm (m, 4H, —CH ₂ —)
1.2-1.33 ppm (m, 4H, —CH ₂ —)
_{0.88ppm (t, 3H, -CH 3} )
_{0.87ppm (t, 3H, -CH 3} )

[Synthesis Example 15: 2- (2,4-diphenylimidazol-1-yl) succinic acid bis (2
-Synthesis of ethylhexyl)
A 200 mL four-necked flask was charged with 20.0 g (0.06 mol) of bis (2-ethylhexyl) fumarate, 30 mL of acetonitrile, and 19.41 g (0.09 mol) of 2,4-diphenylimidazole, and stirred at 25 ° C. DBU2.7g (0.02mol) was dripped there, and it was made to react at 25 degreeC for 20 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid was purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (2,4-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl). I got it. The obtained 2- (2,4-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 7.6 g, and the yield was 23%.
In 2- (2,4-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl), the elimination reaction of the protecting group started under the temperature condition of 283 ° C., and 2- (2,4-diphenylimidazole) It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in -1-yl) succinic acid bis (2-ethylhexyl) was eliminated.

In addition, ¹ H-NMR spectrum of 2- (2,4-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) obtained by Synthesis Example 15 (using “Ascend 400” manufactured by Bruker, internal standard substance) : Tetramethoxysilane, solvent: CDCl ₃ ) is as shown in FIG. 15, and the attribution is as follows.
7.81-7.84 ppm (m, 2H, Ar-H)
7.68-7.71 ppm (m, 2H, Ar-H)
7.44-7.51 ppm (m, 3H, Ar-H)
7.34-7.38 ppm (m, 3H, Ar-H)
7.22-7.26 ppm (m, 1H, Ar-H)
5.44 ppm (t, 1H, —CO—CH—)
4.01-4.16ppm (m, 2H, -CO- OCH 2 -)
3.93-4.01ppm (m, 2H, -CO- OCH 2 -)
3.30 ppm (dd, 1H, —CO—CH ₂ —)
2.98 ppm (dd, 1H, —CO—CH ₂ —)
1.49-1.54 ppm (m, 2H, -CH-)
1.18-1.31 ppm (m, 16H, —CH ₂ —)
_{0.79-0.88ppm (m, 12H, -CH 3} )

[Synthesis Example 16: Synthesis of bis (2-ethylhexyl) 2- (4,5-diphenylimidazol-1-yl) succinate]
A 200 mL four-necked flask was charged with 12.4 g (0.04 mol) of bis (2-ethylhexyl) fumarate, 15 mL of acetonitrile, and 8.0 g (0.04 mol) of 4,5-diphenylimidazole, and stirred at 25 ° C. DBU2.8g (0.02mol) was dripped there and it was made to react at 25 degreeC for 24 hours. After completion of the reaction, extraction was performed with 20 mL of ethyl acetate and 80 mL of water, and the separated organic layer was concentrated. The obtained concentrated liquid is purified by silica gel column chromatography (ethyl acetate / hexane = 1/4) to obtain liquid 2- (4,5-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl). I got it. The obtained 2- (4,5-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) was 13.2 g and the yield was 65%.
2- (4,5-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) starts the elimination reaction of the protecting group under the temperature condition of 259 ° C. It was confirmed by NMR analysis that bis (2-ethylhexyl) succinate in -1-yl) succinic acid bis (2-ethylhexyl) was eliminated.

In addition, ¹ H-NMR spectrum of 2- (4,5-diphenylimidazol-1-yl) succinic acid bis (2-ethylhexyl) obtained by Synthesis Example 16 (using “Ascend 400” manufactured by Bruker, internal standard substance) : Tetramethoxysilane, solvent: CDCl ₃ ) are as shown in FIG. 16, and their attribution is as follows.
7.72 ppm (s, 1H, Ar-H)
7.44-7.48 ppm (m, 5H, Ar-H)
7.35-7.39 ppm (m, 2H, Ar-H)
7.11-7.21 ppm (m, 3H, Ar-H)
5.02 ppm (t, 1H, -CO-CH-)
3.97-4.11 ppm (m, 4H, —CO—OCH ₂ —)
3.21 ppm (dd, 1H, —CO—CH ₂ —)
2.99 ppm (dd, 1H, —CO—CH ₂ —)
1.50-1.53 ppm (m, 2H, -CH-)
1.21-1.31 ppm (m, 16H, —CH ₂ —)
0.81-0.89 ppm (m, 12H, —CH ₃ )

The measurement of the desorption temperature of the protecting group was performed by the following method.
(Measurement of desorption temperature)
The imidazole compound synthesized according to the synthesis example is put in an aluminum pan with a lid, and DSC measurement (using “Diamond DSC” manufactured by Parkin Elmer, measurement temperature range: 30 ° C. to 350 ° C., heating rate: 10 ° C./min) went.

[Examples 1 to 16, Comparative Examples 1 to 10]
Each imidazole compound obtained in Synthesis Examples 1 to 16 is used as a curing agent in Examples 1 to 16, and as a curing agent in Comparative Example, an imidazole compound corresponding to an active species of each imidazole compound obtained in Synthesis Example. (Comparative Examples 1-6 and 8-10) and conventional fine powder imidazole-based latent curing agent (trade name: 2MI.AZ, 2,4-diamino-6- [2- (2-methyl-1- The following evaluation was performed using (imidazolyl) ethyl] -3.4.5-triazine (manufactured by Nippon Synthetic Chemical Industry Co., Ltd.) (Comparative Example 7).

[Storage stability test (pot life test)]
An epoxy resin composition was prepared by adding and mixing the curing agents of Examples 1 to 16 and Comparative Examples 1 to 10 to a bisphenol A type epoxy resin (trade name: jER828, manufactured by Mitsubishi Chemical Corporation). In addition, the addition amount of the hardening | curing agent of Examples 1-16 is 30 mmol with respect to 100 weight part of bisphenol A type epoxy resins, or 5 weight part or 100 g of resin, and addition of the hardening | curing agent of Comparative Examples 1-10 The amount is a weight corresponding to the same number of moles as the addition amount (number of moles) of the corresponding curing agents of Examples 1 to 16.
These compositions were charged into a sealable 150 mL glass container, and a pot life test at 23 ° C. was performed. The viscosity was measured with a Brookfield viscometer, and the time required to reach twice the initial viscosity of the composition immediately after preparation was taken as the pot life value. The results of the storage stability test are shown in Tables 1-9.

[Curing property test]
In the same manner as in the above storage stability test, epoxy resin compositions were prepared using the curing agents of Examples 1 to 16 and Comparative Examples 1 to 10. These compositions were subjected to a curability test at 150 ° C. The curability test was performed by using 2 g of each composition and measuring the gelation time using a gel time tester (manufactured by Yasuda Seiki Seisakusyo Co., Ltd.). The result of a sclerosis | hardenability test is combined with Tables 1-9, and is shown.

  From the result shown in Tables 1-9, since Examples 1-16 have extended pot life value compared with Comparative Examples 1-6 and 8-10 which correspond to each active site, Example 1 It can be seen that ˜16 curing agents are curing agents having very excellent storage stability even when used as a one-component curing agent.

  In addition, from the results shown in Tables 1, 5, and 8, Examples 1, 7, 8, 14, and 15 have shorter gel times than Comparative Examples 1, 5, and 9, and Examples 1, 7 , 8, 14 and 15 are better than those of Comparative Examples 1, 5, and 9 in curing performance.

  From the results shown in Tables 2 to 4, 6, 7, and 9, Examples 2 to 6, 9 to 13, and 16 have a slightly longer gelation time than Comparative Examples 2 to 4, 6, 8, and 10. However, the gelation time is about the same as the time required for curing a normal epoxy resin, and it can be seen that it is sufficiently applicable to actual use.

  Further, from the results shown in Table 6, Examples 9 to 11 have a slightly longer gelation time than Comparative Example 7 using a fine powdery latent imidazole, but cured normal epoxy resins. It can be seen that the gelation time is about the same as the time required for making it, and can be applied to actual use. Furthermore, it turns out that Examples 9-11 are the hardening agents which have the pot life value equivalent to the comparative example 7, and have the outstanding storage stability equivalent to the comparative example 7. In addition, since the curing agent of Comparative Example 7 is in the form of a powder, it may require troublesome mixing work, and may cause problems such as failure to obtain uniform mixing and failure to cure. Since the curing agents 9 to 11 are liquid, they are excellent in uniform mixing properties and easy to handle.

[Example 17, comparative example 11]
Using the compound obtained in Synthesis Example 5 as the curing agent of Example 17, and using the imidazole compound (Comparative Example 11) corresponding to the active species of the compound obtained in Synthesis Example 5 as the curing agent of Comparative Example, The following evaluation was performed.

[Storage stability test (pot life test)]
An episulfide resin composition was prepared by adding and mixing the curing agents of Example 17 and Comparative Example 11 to hydrogenated bisphenol A type episulfide resin (trade name: YL7007, manufactured by Mitsubishi Chemical Corporation). In addition, the addition amount of the curing agent of Example 17 is 30 mmol with respect to 100 g of hydrogenated bisphenol A type episulfide resin, and the addition amount of the curing agent of Comparative Example 11 is the addition amount of the corresponding curing agent of Example 17. The weight is equivalent to the same number of moles as (number of moles).
These compositions were charged into a sealable 150 mL glass container, and a pot life test at 23 ° C. was performed. The viscosity was measured with a Brookfield viscometer, and the time required to reach twice the initial viscosity of the composition immediately after preparation was taken as the pot life value. Table 10 shows the results of the storage stability test.

[Curing property test]
An episulfide resin composition was prepared using the curing agents of Example 17 and Comparative Example 11 in the same manner as in the above storage stability test. These compositions were subjected to a curability test at 120 ° C. The curability test was performed by using 2 g of each composition and measuring the gelation time using a gel time tester (manufactured by Yasuda Seiki Seisakusyo Co., Ltd.). The results of the curability test are also shown in Table 10.

  From the results shown in Table 10, although Example 17 has a slightly longer gelation time than Comparative Example 11 corresponding to the active site of the curing agent, it is necessary for curing an ordinary episulfide resin. It can be seen that the gelation time is about the same as the time, and is sufficiently applicable to actual use. Furthermore, since the pot life value of Example 17 is longer than that of Comparative Example 11, the curing agent of Example 17 has excellent storage stability even when used as a one-component curing agent. It turns out that it is a hardening | curing agent which has.

  From the above, it can be seen that when the imidazole compound of the present invention is used as a curing agent, for example, it has excellent storage stability and good curability even when used as a one-component curing agent. Furthermore, the imidazole compound of the present invention is usually a liquid in the normal state, and when used as a curing agent, it does not require a dissolving operation and is excellent in uniform mixing, so that it can be handled easily. I understand.

  The imidazole compound of the present invention is, for example, a curing agent or a curing catalyst for curing a thermosetting compound such as an epoxy compound or an episulfide compound, particularly a curing for curing a thermosetting resin such as an epoxy resin or an episulfide resin. It is useful as an agent, a curing catalyst, a urethane curing catalyst, a pharmaceutical intermediate, an agrochemical intermediate, a rust inhibitor, and the like. When the imidazole compound of the present invention is used as a curing agent, the imidazole compound of the present invention has good curability and has higher storage stability than a conventional imidazole curing agent, and as a one-part curing agent. Since it has excellent storage stability and good curability even when used, it is useful as a curing agent for anionic curable compounds such as epoxy compounds and episulfide compounds. In particular, it is useful as a curing agent for anion curable compounds in the field of electronic materials.

Claims (1)

Imidazole compounds represented by the following general formula (I).

[Where,
R1 and R2 are each independently an alkyl group having 4 to 20 carbon atoms,
R3 to R5 are each independently a group consisting of a hydrogen atom, an alkyl group having 1 to 17 carbon atoms, an aryl group having 6 to 17 carbon atoms, and a heteroaryl group having 3 to 15 carbon atoms containing at least one heteroatom. Any one atom or group selected.
However, a compound in which R1 and R2 are both butyl groups and R3 to R5 are all hydrogen atoms is excluded. ]

Images